CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 24 enrolled
Drug / intervention
Salsalate Oral Tablet +1 moredrug
Likely dose
Salsalate Oral Tablet 1500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03482440
NCT03482440Early Ph 1Completed

Role of Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclamptic Pregnancy

University of Iowa·interventional·Posted Mar 29, 2018·Updated Jun 3, 2025

In Brief

A Early Phase 1 clinical trial evaluating Salsalate Oral Tablet and Placebo Oral Tablet for Preeclampsia. Completed, enrolled 24 participants across 2 sites.

Detailed Summary

Women who develop preeclampsia during pregnancy are more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. The purpose of this investigation is to 1) determine the mechanisms contributing to this lasting blood vessel damage and chronic inflammation, and to 2) identify factors (both physiological and pharmacological) that mitigate these negative effects in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPreeclampsia
CountriesUnited States

Timeline

Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedMar 29, 2018
Enrollment StartAug 26, 2018
Primary CompletionJul 11, 2019
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.3 years ago

Interventions

Salsalate Oral Tabletdrug

1500mg twice daily for 4 days prior to experimental testing

Placebo Oral Tabletdrug

Placebo oral table twice daily for 4 days prior to experimental testing